Exhibit 99.1

Contact:
Rob Seim		Omnicell, Inc.
Chief Financial Officer		1201 Charleston Road
800-850-6664, ext. 6478		Mountain View, CA 94043
rob.seim@omnicell.com

Omnicell Announces Second Quarter 2009 Results

MOUNTAIN VIEW, Calif. — July 23, 2009 — Omnicell, Inc. (NASDAQ: OMCL), a leading provider of system solutions to acute healthcare facilities, today announced results for its second quarter ended June 30, 2009.

GAAP results: Revenue for the second quarter of 2009 was $52.6 million, up $0.4 million or 0.8% from the first quarter of 2009, and down $10.7 million or 16.9% from the second quarter of 2008.

Second quarter 2009 net income as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $0.9 million, or $0.03 per diluted share. This compares to net loss of $1.9 million, or ($0.06) per diluted share in the first quarter of 2009 and net income of $2.8 million, or $0.08 per diluted share in the second quarter of 2008.

Non-GAAP results: Excluding the impact on our results of recording $2.4 million in share-based compensation expense related to SFAS No. 123R, non-GAAP net income was $3.3 million for the second quarter of 2009, or $0.10 per diluted share. This compares to non-GAAP net income of $2.1 million, or $0.07 per diluted share for the first quarter of 2009, which as well as excluding $2.5 million in stock compensation expense, also excludes a charge of $1.5 million (net of tax) relating to a reduction in force.  Second quarter 2009 results compare to non-GAAP net income of $5.7 million, or $0.17 per diluted share for the second quarter of 2008.

“I am pleased with our performance in Q2 2009,” said Randall Lipps, Omnicell President, Chairman and CEO. “We continuously hear from our customers that our medication and supply automation solutions are enabling physicians and nurses to spend more time delivering care, rather than time consuming manual processes. Our solutions continue to attract new customers who are committed to having the safest and most effective automation capabilities in their hospitals.”

Omnicell Conference Call Information

Omnicell will hold a conference call today at 1:30 p.m. PDT to discuss second quarter financial results. The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations. The Conference ID # is 20153924. Internet users can access the conference call at http://ir.omnicell.com/events.cfm. A replay of the call will be available today at approximately 2:30 p.m. PDT and will be available until 8:59 p.m. PDT on July 30. The replay access numbers are 1-800-642-1687 within the U.S. and 1-706-645-9291 for all other locations, conference code # 20153924.

About Omnicell

Omnicell, Inc. (NASDAQ: OMCL) is a leading provider of systems and software solutions targeting patient safety and operational efficiency in healthcare facilities. Since 1992, Omnicell has worked to enhance patient safety and allow clinicians to spend more time with their patients.

Omnicell medication-use product lines include solutions for the central pharmacy, nursing unit, operating room, and patient bedside. Solutions range from large central pharmacy “smart inventory” carousels to small handheld devices. From the point at which a medication arrives at the receiving dock to the time it is administered, Omnicell systems store it, package it, bar code it, order it, issue it, and provide information and controls on its use and reorder.

Omnicell supply product lines provide a healthcare institution with fast, effective control of costs, capture of charges for payer reimbursement, and timely reorder of supplies. Products range from high-security closed-cabinet systems and software to open-shelf and combination solutions in the nursing unit, cath lab and operating room.

Omnicell’s mission is to provide the best customer experience in healthcare, helping hospitals reduce medication errors, operate more efficiently, and decrease costs. For more information, visit www.omnicell.com.

Forward-Looking Statements

To the extent any statements contained in this release deal with information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside Omnicell’s control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. The risk factors are described in the Company’s Securities and Exchange Commission (SEC) filings and include, without limitation, the unfavorable general economic and market conditions, the tightening in the credit market, the continued growth and acceptance of our products and services and the continued growth of the clinical automation and workflow automation market generally, the potential of increasing competition, the ability of the company to grow product backlog, retain key personnel, cut expenses, manage future changes in revenue levels, develop new products and integrate acquired products or intellectual property in a timely and cost-effective manner, and improve sales productivity. Prospective investors are cautioned not to place undue reliance on forward-looking statements.

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). Our management evaluates and makes operating decisions using various performance measures. In addition to Omnicell’s GAAP results, we also consider non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP earnings per diluted share.  These non-GAAP results should not be considered as an alternative to gross profit, operating expenses, net income, earnings per diluted share, or any other performance measure derived in accordance with GAAP.  We present these non-GAAP results because we consider them to be important supplemental measures of Omnicell’s performance.

Our non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP earnings per diluted share are exclusive of certain items to facilitate management’s review of the comparability of Omnicell’s core operating results on a period to period basis because such items are not related to Omnicell’s ongoing core operating results as viewed by management. We define our “core operating results” as those revenues recorded in a particular period and the expenses incurred within that period that directly drive operating income in that period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we should invest in research and development, fund infrastructure growth and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results, management specifically adjusted for the following excluded items:

a)  Stock-based compensation expense impact of SFAS No. 123R.  We recognize equity plan-related compensation expenses, which represents the fair value of all share-based payments to employees, including grants of employee stock options, as required under SFAS No. 123 (revised 2004), “Share-Based Payment” (SFAS No.123R).

b) Restructuring charges (net of tax).  We incurred charges for employee severance in connection with a reduction in force in the first quarter of 2009, which was designed to align our cost structure with current business expectations.  These charges are not expected to be recurring and, as a non-recurring event, the financial impact is excluded from our non-GAAP results.

Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell’s control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational, or non-cash expenses involving stock option grants.

We believe that the presentation of these non-GAAP financial measures is warranted for several reasons:

1) Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell’s financial performance by excluding the impact of items which may obscure trends in the core operating results of the business;

2) Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors’ ability to compare our performance across financial reporting periods;

3) These non-GAAP financial measures are employed by Omnicell’s management in its own evaluation of performance and are utilized in financial and operational decision making processes, such as budget planning and forecasting; and

4) These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which use similar financial measures to supplement their GAAP results, thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance.

Set forth below are additional reasons why share-based compensation expense related to SFAS No. 123R is excluded from our non-GAAP financial measures:

i)  While share-based compensation calculated in accordance with SFAS No.123R constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of stock-based compensation expense to assist management and investors in evaluating our core operating results.

ii) We present SFAS No.123R share-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of share-based compensation, under SFAS No.123R, are dependent upon the trading price of Omnicell’s common stock and the timing and exercise by employees of their stock options.  As a result of these timing and market uncertainties the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results.

As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell’s GAAP results.  In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:

· Omnicell’s stock option and stock purchase plans are important components of incentive compensation arrangements and will be reflected as expenses in Omnicell’s GAAP results for the foreseeable future under SFAS No.123R.

· Other companies, including other companies in Omnicell’s industry, may calculate non-GAAP financial measures differently than Omnicell, limiting their usefulness as a comparative measure.

Pursuant to the requirements of SEC Regulation G, a detailed reconciliation between Omnicell’s non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release and in Omnicell’s SEC filings.

OMCL-E

Omnicell, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share data, unaudited)

		Three Months Ended									Six Months Ended
		June 30, 2009			March 31, 2009			June 30, 2008			June 30, 2009			June 30, 2008
Revenues:
Product		$	41,983		$	42,295		$	52,870		$	84,278		$	105,286
Services and other revenues		10,660			9,909			10,504			20,569			20,179
Total revenue		52,643			52,204			63,374			104,847			125,465
Cost of revenues:
Cost of product revenues		19,175			20,280			24,349			39,455			48,319
Cost of services and other revenues		6,539			6,895			6,665			13,434			12,440
Restructuring charges		—			1,209			—			1,209			—
Total cost of revenues		25,714			28,384			31,014			54,098			60,759
Gross profit		26,929			23,820			32,360			50,749			64,706
Operating expenses:
Research and development		4,574			3,977			4,978			8,551			9,255
Selling, general, and administrative		21,038			21,499			22,878			42,537			46,085
Restructuring charges		—			1,315			—			1,315			—
Total operating expenses		25,612			26,791			27,856			52,403			55,340
Income (loss) from operations		1,317			(2,971		)	4,504			(1,654		)	9,366
Other income and expense, net		194			182			722			376			2,131
Income (loss) before provision for (benefit from) income taxes		1,511			(2,789		)	5,226			(1,278		)	11,497
Provision for (benefit from) income taxes		607			(918		)	2,473			(311		)	5,011
Net income (loss)		$	904		$	(1,871	)	$	2,753		$	(967	)	$	6,486
Net income (loss) per share:
Basic		$	0.03		$	(0.06	)	$	0.09		$	(0.03	)	$	0.20
Diluted		$	0.03		$	(0.06	)	$	0.08		$	(0.03	)	$	0.19
Weighted average shares outstanding:
Basic		31,578			31,453			31,716			31,516			32,954
Diluted		31,961			31,453			32,549			31,516			34,065

Omnicell, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

		June 30,			December 31,
		2009			2008
		(unaudited)			(1)
ASSETS
Current assets:
Cash and cash equivalents		$	126,426		$	120,439
Accounts receivable, net		67,655			56,472
Inventories		9,624			12,957
Prepaid expenses		9,787			9,310
Deferred tax assets		14,871			14,871
Other current assets		7,040			10,938
Total current assets		235,403			224,987
Property and equipment, net		14,326			16,180
Non-current net investment in sales-type leases		9,531			10,896
Goodwill		24,982			24,982
Other intangible assets		5,362			6,706
Non-current deferred tax assets		15,704			15,889
Other assets		9,298			8,902
Total assets		$	314,606		$	308,542
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	10,584		$	9,377
Accrued compensation		8,574			8,889
Accrued liabilities		14,249			10,187
Deferred service revenue		12,830			12,084
Deferred gross profit		12,334			16,648
Obligation resulting from sale of receivables		87			170
Total current liabilities		58,658			57,355
Long-term deferred service revenue		15,971			16,782
Other long-term liabilities		776			848
Total liabilities		75,405			74,985
Stockholders’ equity:
Total stockholders’ equity		239,201			233,557
Total liabilities and stockholders’ equity		$	314,606		$	308,542

(1) Information derived from our December 31, 2008 audited Consolidated Financial Statements.

Omnicell, Inc.

Reconciliation of GAAP to Non-GAAP

(In thousands, except per share data, unaudited)

		Three months ended
		June 30, 2009						March 31, 2009							June 30, 2008
		Net income			Earnings per share- diluted			Net income (loss)			Earnings (loss) per share - diluted				Net income			Earnings per share- diluted
GAAP		$	904		$	0.03		$	(1,871	)	$	(0.06	)		$	2,753		$	0.08
Non-GAAP Adjustments:
SFAS No. 123(R) adjustment (a)
Gross Margin		287						379							416
Operating Expenses		2,087						2,105							2,517
Restructuring cost (net of tax) (b)
Gross profit								735
Operating expenses								799
		2,374			0.07			4,018			0.13				2,933			0.09
Non-GAAP		$	3,278		$	0.10		$	2,147		$	0.07			$	5,686		$	0.17
		Six months ended
		June 30, 2009						June 30, 2008
		Net income (loss)			Earnings (loss) per share - diluted			Net income			Earnings per share- diluted
GAAP		$	(967	)	$	(0.03	)	$	6,486		$	0.19
Non-GAAP Adjustments:
SFAS No. 123(R) adjustment (a)
Gross Margin		665						926
Operating Expenses		4,193						5,074
Restructuring cost (net of tax) (b)
Gross profit		735
Operating expenses		799
		6,392			0.20			6,000			0.18
Non-GAAP		$	5,425		$	0.17		$	12,486		$	0.37

(a) This adjustment reflects the accounting impact of non-cash share-based compensation expense related to the impact of FAS123R for the periods shown.

(b) This is the net of tax impact of the restructuring activities executed during the first quarter of 2009.